Your prescription costs might change overnight. It happens to thousands of patients every year when insurance plans update their formularies-the lists of drugs they cover. For many, this means a sudden switch from a brand-name drug to a generic version, or worse, a higher copay for the same medication. With the major shifts brought by the Inflation Reduction Act (IRA) fully in effect, understanding these changes is no longer optional; it’s essential for keeping your health and your budget stable.
In 2025, the landscape shifted dramatically with the introduction of a $2,000 annual out-of-pocket cap for Medicare Part D enrollees. Now, as we move into 2026, new rules regarding drug price negotiations and biosimilar adoption are reshaping what you pay at the pharmacy counter. This guide breaks down how formulary updates work, why insurers push generic switching, and exactly what steps you can take to protect yourself from unexpected costs.
What Are Formulary Updates and Why Do They Happen?
A formulary is a list of prescription medications covered by an insurance plan. Think of it as the menu of drugs your insurer agrees to pay for. These menus change regularly, usually once a year, effective January 1st. Insurance companies and Pharmacy Benefit Managers (PBMs) like CVS Caremark, OptumRx, and Express Scripts adjust these lists to balance cost containment with regulatory compliance.
The primary driver behind these updates is money. Insurers want to steer patients toward lower-cost options, specifically generics and biosimilars, to reduce overall spending. According to Milliman’s analysis, 78% of standalone Prescription Drug Plans (PDPs) implemented substantial generic substitution policies in 2025. This trend continues into 2026, with projections showing that 65% of formularies will enforce mandatory generic substitutions where alternatives exist.
Formulary changes typically happen through four mechanisms:
- Complete Exclusions: A drug is removed from coverage entirely.
- Tier Reassignments: A drug moves to a higher tier, increasing your copay.
- Prior Authorization: Your doctor must prove medical necessity before the insurer pays.
- Step Therapy: You must try cheaper alternatives first before getting your preferred drug.
The Impact of the Inflation Reduction Act on Your Costs
The Inflation Reduction Act (IRA) is a federal law signed in 2022 that overhauled Medicare prescription drug pricing. Its effects are now fully visible in 2026. The most significant benefit for patients is the hard cap on out-of-pocket expenses. Once you spend $2,000 on covered drugs in a year, your plan pays 100% of the rest. This eliminated the infamous "donut hole" coverage gap.
However, this cap comes with trade-offs. To keep premiums manageable while paying for the cap, insurers are aggressively managing drug utilization. They do this by restricting access to high-cost brand-name drugs and pushing generic switches. For example, in 2025, AARP estimated that 3.2 million beneficiaries saved an average of $1,500 due to the cap. But many also faced increased scrutiny on their prescriptions.
Starting January 1, 2026, the Medicare Drug Price Negotiation Program (MDPNP) requires all Part D plans to cover specific negotiated drugs. This includes high-cost medications like Stelara (ustekinumab), Prolia (denosumab), and Xolair (omalizumab). While this ensures coverage, it may lead insurers to tighten restrictions on other non-negotiated brands to offset costs.
Generic Switching vs. Biosimilars: What’s the Difference?
When your insurer suggests a "generic switch," they usually mean replacing a brand-name small-molecule drug with its generic equivalent. Generics contain the same active ingredients and work the same way, but they cost significantly less. Tier 1 preferred generics often have copays between $1 and $10 in 2025-2026 plans.
For complex biological drugs-like those used for arthritis, cancer, or Crohn’s disease-the alternative is a biosimilar is a biologic medical product highly similar to an FDA-licensed reference product. Biosimilars are not identical copies like generics; they are large, complex molecules. However, the FDA has tightened standards, giving PBMs confidence to substitute them even without formal "interchangeable" designations.
| Feature | Generic Drug | Biosimilar |
|---|---|---|
| Composition | Identical active ingredient to brand | Highly similar to reference biologic |
| Manufacturing | Synthetic chemical process | Living cell systems (complex) |
| Cost Savings | Often 80-85% less than brand | Typically 15-30% less than originator |
| Switching Ease | Pharmacist can often swap automatically | May require doctor approval or prior authorization |
| Example | Lisinopril (for blood pressure) | Amjevita (biosimilar for Humira) |
User feedback highlights mixed experiences. Some patients report seamless transitions with savings, such as one user who switched from Humira to Amjevita and saved $450 monthly with no loss in effectiveness. Others worry about subtle differences in side effects or efficacy, particularly with chronic conditions.
How to Spot Formulary Changes Before They Hit You
You cannot afford to be caught off guard. CMS mandates that insurers provide at least 60 days' advance notice for formulary changes affecting existing medications. For newly approved generics, this window shrinks to 30 days. Here is how to stay ahead:
- Check the Summary of Coverage (SOC): Every fall, between October and December, your insurer sends an SOC. This document details the next year’s formulary. Look for sections titled "Formulary Changes" or "Drug List Updates."
- Use Online Tools: Most major insurers offer online portals where you can check if your current drugs are still covered and at what tier. Cigna, Aetna, and UnitedHealthcare all provide these tools.
- Consult Your Pharmacist: Pharmacists see these changes daily. Ask them during your next refill if any of your medications are likely to be moved or excluded.
- Review Notification Letters: If a drug is being excluded or moved to a higher tier, you should receive a specific written notification. Keep these letters; they are crucial for filing exceptions.
For instance, Priority Health’s 2025 formulary changes focused heavily on diabetes and respiratory drugs. Patients on insulin or inhalers needed to review their notices carefully to avoid surprise copay hikes.
Filing for Exceptions: When the Plan Says No
If your preferred drug is no longer covered or has moved to a higher tier, you don’t always have to switch. You can file a formulary exception is a request to have your plan cover a drug that is otherwise restricted or excluded. This process allows your doctor to argue that the alternative drugs are medically inappropriate for you.
There are two types of requests:
- Standard Exception: Processed within 72 hours. Use this for non-urgent needs.
- Expedited Exception: Processed within 24 hours. Use this if delaying treatment would seriously harm your health.
Success rates vary. CMS data from 2024 shows an 82.3% approval rate for tiering exceptions (lowering your copay) but only a 47.1% approval rate for completely excluded drugs. To improve your chances, your doctor must provide detailed clinical evidence explaining why the generic or alternative won’t work for you. This might include past failed trials of the alternative or specific adverse reactions.
Cigna’s member survey revealed that while 73% of members successfully obtained exceptions, 38% reported waiting 10-14 days for resolution. This delay can cause dangerous medication interruptions. Always ask your doctor to submit the request immediately upon receiving notice of a change.
Navigating the 2026 Landscape: Key Trends to Watch
As we settle into 2026, several trends are shaping prescription coverage:
Mandatory Coverage of Negotiated Drugs: Under the MDPNP, plans must cover drugs like Stelara and Prolia. This is a win for patients on these therapies, but insurers may respond by tightening step therapy protocols for other autoimmune or bone density drugs.
Accelerated Biosimilar Adoption: The FDA approved 17 biosimilars in 2024 alone. By 2027, biosimilar market penetration could reach 45% for targeted therapies. Expect more automatic switches at the pharmacy counter for biologics.
Reduced Specialty Exclusions: Interestingly, some PBMs are excluding fewer specialty drugs than before. CVS Caremark reduced its specialty exclusions by 57% from 2024 to 2025. This suggests a shift toward managing costs through tiering and prior authorization rather than outright denial.
Profitability Pressures: J.P. Morgan projects that IRA provisions will reduce Part D plan profitability by 18-22% through 2027. This financial pressure may lead to stricter formulary restrictions unless premiums rise. Stay alert for premium increases alongside formulary tightening.
Practical Steps to Manage Your Medication Costs
Don’t wait until January to act. Start preparing now:
- Inventory Your Meds: Make a list of all current prescriptions, including dosages and frequencies.
- Compare Plans Early: During Open Enrollment (October 15 - December 7), use the Medicare Plan Finder tool to compare formularies. Don’t just look at premiums; check the drug tiers.
- Talk to Your Doctor: Discuss potential alternatives proactively. If a generic exists and is safe for you, agree to switch before the insurance forces it. This avoids disruption.
- Utilize Transitional Supplies: If a change takes effect unexpectedly, you are entitled to a 30-day transitional supply. Use this time to file an exception or find a new solution.
- Monitor Out-of-Pocket Spending: Track your cumulative drug costs. Knowing when you hit the $2,000 cap helps you plan for the rest of the year.
Remember, formulary updates are not personal attacks; they are business decisions driven by regulation and economics. But your health is personal. By staying informed and proactive, you can navigate these changes without compromising your care or your wallet.
What is a formulary exclusion?
A formulary exclusion means your insurance plan will not cover a specific drug at all. You would have to pay the full retail price out-of-pocket. This is different from a tier change, where the drug is still covered but costs more.
How much notice do I get before my drug is dropped from coverage?
CMS requires insurers to give at least 60 days' advance notice for most formulary changes affecting existing medications. For newly approved generics, the notice period is shorter, typically 30 days.
Can I refuse a generic switch?
You can refuse, but you may lose coverage for that drug. To keep your brand-name drug covered, you must file a formulary exception with your doctor's support. Without an approved exception, you will likely face higher costs or no coverage.
What is the $2,000 out-of-pocket cap?
Implemented under the Inflation Reduction Act, this cap limits what Medicare Part D beneficiaries pay for covered drugs each year. Once you spend $2,000, your plan covers 100% of remaining costs. This applies to both brand-name and generic drugs.
Are biosimilars as effective as brand-name biologics?
Yes. Biosimilars must demonstrate no clinically meaningful differences in safety, purity, and potency compared to the reference product. Many patients experience identical results with significant cost savings, though individual responses can vary.
When should I review my formulary?
Review your formulary annually during Open Enrollment (October-December) for the upcoming year. Also, check immediately if you receive a notification letter about a specific drug change. Proactive reviews prevent surprises.
What is step therapy?
Step therapy requires you to try one or more lower-cost, covered drugs before your insurer will pay for your preferred medication. Your doctor must approve each step, and you can appeal if the initial drugs fail or cause side effects.
Will my drug prices go up in 2026?
Prices depend on your plan and drug tier. While the $2,000 cap protects against extreme costs, tier reassignments can increase copays for specific drugs. Additionally, premium increases may occur as insurers adjust to IRA profitability pressures.
